Author

Barbara Belletti

Centro di Riferimento OncologicoORCID 0000-0003-2249-0285Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Alessandro SarcinellaiD· 1 shared Alessia LamolinaraiD· 1 shared Andrea Scavuzzo· 1 shared Andrew C.B. CatoiD· 1 shared Christine BlattneriD· 1 shared Christoph W. GrathwoliD· 1 shared Daniela TavernaiD· 1 shared Daniela TosoniiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandro SarcinellaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

p140Cap enhances breast cancer chemosensitivity by limiting an ABCC1-enriched stem-like compartment via β-Catenin inhibition

Andrea Scavuzzo, Matteo Poncina, Alessia Lamolinara, Alessandro Sarcinella, Mahdis Jahanbin, Maria Grazia Filippone, Laura Bottoni, Francesco Antonio Tucci, Yaron Vinik, Sima Lev, Manuela Iezzi, Ugo Ala, Daniela Taverna, Francesca Orso, Barbara Belletti, , Vincenzo Salemme

This study shows p140Cap improves chemotherapy response in breast cancer by reducing stem-like cells and enhancing drug retention through β-Catenin inhibition.

bioRxiv · Aug 18, 2026 · PreprintCancer Biology

Distinct 2-phenyl-imidazo pyridine derivatives drive ER degradation and selectively impair proliferation of ER+ breast cancer cells via the aryl hydrocarbon receptor

Katrin Koellisch, Christine Blattner, Stefano Motta, Janine Wesslowski, Melanie Rothley, Simone Büchel, Savannah Sirounian, Julia Müller, Marina Grimaldi, Jutta Stober, Zoe Wammetsberger, Mengwu Pan, René Houtman, Christoph W. Grathwol, Ilenia Segatto, , Andrew C.B. Cato

The paper identifies X15695 as an AHR ligand that promotes ER degradation and inhibits ER+ breast cancer cell proliferation more effectively than fulvestrant.

bioRxiv · Jul 28, 2025 · PreprintCancer Biology